Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02141542
Title Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors F. Stephen Hodi, MD
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.